| ￥3300 | |
| Z05966-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1 EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 37.3 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 45-50 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized AREG hFc Chimera, Human, hFc Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-AREG Antibody, hFc-Avi Tag with the EC50 of 37.4ng/ml determined by ELISA. »
The purity of AREG hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »
AREG hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Amphiregulin (AREG) is a member of the epidermal growth factor (EGF) family and is expressed in a plethora of cancers. Tumour growth and metastasis were decreased by AREG silencing in an orthotopic model of pancreatic cancer. AREG may play a critical role in cell migration, invasion, and EMT by activating the EGFR/ERK/NF‑κB signalling pathway in pancreatic cancer cells. |
| Synonyms | Amphiregulin; AR; SDGF; AREG; AREGB; CRDGF; MGC13647 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
